Cargando…
Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope
Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells found in the tumor microenvironment. TLS can influence primary hepatic carcinoma (PHC) occurrence and have an active role in cancer. TLS can promote or inhibit the growth of PHC depending on their location, and although ava...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278517/ https://www.ncbi.nlm.nih.gov/pubmed/35844587 http://dx.doi.org/10.3389/fimmu.2022.870458 |
_version_ | 1784746203839201280 |
---|---|
author | Jia, Weili Zhang, Tianchen Yao, Qianyun Li, Jianhui Nie, Ye Lei, Xinjun Mao, Zhenzhen Wang, Yanfang Shi, Wen Song, Wenjie |
author_facet | Jia, Weili Zhang, Tianchen Yao, Qianyun Li, Jianhui Nie, Ye Lei, Xinjun Mao, Zhenzhen Wang, Yanfang Shi, Wen Song, Wenjie |
author_sort | Jia, Weili |
collection | PubMed |
description | Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells found in the tumor microenvironment. TLS can influence primary hepatic carcinoma (PHC) occurrence and have an active role in cancer. TLS can promote or inhibit the growth of PHC depending on their location, and although available findings are controversial, they suggest that TLS have a protective role in PHC tissues and a non-protective role in paracancerous tissues. In addition, the cellular composition of TLS can also influence the outcome of PHC. As an immunity marker, TLS can act as a marker of immunotherapy to predict its effect and help to identify patients who will respond well to immunotherapy. Modulation of TLS formation through the use of chemokines/cytokines, immunotherapy, or induction of high endothelial vein to interfere with tumor growth has been studied extensively in PHC and other cancers. In addition, new tools such as genetic interventions, cellular crosstalk, preoperative radiotherapy, and advances in materials science have been shown to influence the prognosis of malignant tumors by modulating TLS production. These can also be used to develop PHC treatment. |
format | Online Article Text |
id | pubmed-9278517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92785172022-07-14 Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope Jia, Weili Zhang, Tianchen Yao, Qianyun Li, Jianhui Nie, Ye Lei, Xinjun Mao, Zhenzhen Wang, Yanfang Shi, Wen Song, Wenjie Front Immunol Immunology Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells found in the tumor microenvironment. TLS can influence primary hepatic carcinoma (PHC) occurrence and have an active role in cancer. TLS can promote or inhibit the growth of PHC depending on their location, and although available findings are controversial, they suggest that TLS have a protective role in PHC tissues and a non-protective role in paracancerous tissues. In addition, the cellular composition of TLS can also influence the outcome of PHC. As an immunity marker, TLS can act as a marker of immunotherapy to predict its effect and help to identify patients who will respond well to immunotherapy. Modulation of TLS formation through the use of chemokines/cytokines, immunotherapy, or induction of high endothelial vein to interfere with tumor growth has been studied extensively in PHC and other cancers. In addition, new tools such as genetic interventions, cellular crosstalk, preoperative radiotherapy, and advances in materials science have been shown to influence the prognosis of malignant tumors by modulating TLS production. These can also be used to develop PHC treatment. Frontiers Media S.A. 2022-06-29 /pmc/articles/PMC9278517/ /pubmed/35844587 http://dx.doi.org/10.3389/fimmu.2022.870458 Text en Copyright © 2022 Jia, Zhang, Yao, Li, Nie, Lei, Mao, Wang, Shi and Song https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Jia, Weili Zhang, Tianchen Yao, Qianyun Li, Jianhui Nie, Ye Lei, Xinjun Mao, Zhenzhen Wang, Yanfang Shi, Wen Song, Wenjie Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope |
title | Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope |
title_full | Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope |
title_fullStr | Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope |
title_full_unstemmed | Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope |
title_short | Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope |
title_sort | tertiary lymphatic structures in primary hepatic carcinoma: controversy cannot overshadow hope |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278517/ https://www.ncbi.nlm.nih.gov/pubmed/35844587 http://dx.doi.org/10.3389/fimmu.2022.870458 |
work_keys_str_mv | AT jiaweili tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT zhangtianchen tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT yaoqianyun tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT lijianhui tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT nieye tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT leixinjun tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT maozhenzhen tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT wangyanfang tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT shiwen tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT songwenjie tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope |